Florence Lefranc Selected Research

Galectin 1 (LGALS1)

1/2017	Sensitization of glioblastoma tumor micro-environment to chemo- and immunotherapy by Galectin-1 intranasal knock-down strategy.
4/2016	Development of siRNA-loaded chitosan nanoparticles targeting Galectin-1 for the treatment of glioblastoma multiforme via intranasal administration.
2/2014	Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
10/2013	Altered galectin-1 serum levels in patients diagnosed with high-grade glioma.
5/2012	Galectin-1, a gene preferentially expressed at the tumor margin, promotes glioblastoma cell invasion.
12/2011	Galectin-1 as an oncotarget in gliomas and melanomas.
9/2011	Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior.
4/2011	Galectin-1 and immunotherapy for brain cancer.
1/2010	Galectins and gliomas.
1/2010	Galectin-1 is implicated in the protein kinase C epsilon/vimentin-controlled trafficking of integrin-beta1 in glioblastoma cells.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Florence Lefranc Research Topics

Disease

75	Neoplasms (Cancer) 01/2022 - 05/2002
44	Glioblastoma (Glioblastoma Multiforme) 11/2021 - 05/2002
43	Glioma (Gliomas) 01/2021 - 05/2002
16	Melanoma (Melanoma, Malignant) 09/2016 - 05/2006
8	Brain Neoplasms (Brain Tumor) 01/2022 - 01/2006
5	Neoplasm Metastasis (Metastasis) 01/2016 - 05/2006
5	Oligodendroglioma 05/2011 - 08/2002
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 03/2013 - 03/2006
4	Aneurysm (Aneurysms) 09/2008 - 06/2004
4	Subarachnoid Hemorrhage (Aneurysmal Subarachnoid Hemorrhage) 10/2007 - 03/2002
4	Gliosarcoma 04/2005 - 05/2002
3	Meningioma (Meningiomas) 01/2022 - 06/2011
3	Breast Neoplasms (Breast Cancer) 01/2018 - 08/2007
3	Prostatic Neoplasms (Prostate Cancer) 05/2012 - 03/2006
3	Hypoxia (Hypoxemia) 09/2011 - 05/2008
3	Astrocytoma (Pilocytic Astrocytoma) 05/2011 - 04/2009
2	Head and Neck Neoplasms (Head and Neck Cancer) 09/2016 - 03/2015
2	Kidney Neoplasms (Kidney Cancer) 10/2015 - 05/2006
2	Leukemia 01/2009 - 08/2007
2	Hemorrhage 09/2005 - 08/2002
2	Craniopharyngioma (Craniopharyngiomas) 04/2005 - 01/2003
1	Pituitary Neoplasms (Pituitary Adenoma) 01/2022
1	Fatigue 01/2022
1	Neurofibromatosis 2 (Neurofibromatosis Type II) 11/2020
1	Central Nervous System Neoplasms 04/2016

Drug/Important Bio-Agent (IBA)

25	Temozolomide (Temodar)FDA LinkGeneric 11/2021 - 08/2002
19	Pharmaceutical PreparationsIBA 01/2019 - 03/2006
17	Galectin 1 (LGALS1)IBA 01/2017 - 07/2002
12	Cytostatic AgentsIBA 02/2018 - 04/2003
10	Antineoplastic Agents (Antineoplastics)IBA 01/2019 - 08/2012
8	Biological ProductsIBA 01/2019 - 07/2002
8	Proteins (Proteins, Gene)FDA Link 01/2017 - 08/2002
7	LigandsIBA 04/2010 - 11/2006
6	Adenosine Triphosphatases (ATPase)IBA 05/2013 - 01/2008
6	Sodium-Potassium-Exchanging ATPase (Sodium, Potassium ATPase)IBA 03/2011 - 01/2008
5	Small Interfering RNA (siRNA)IBA 04/2016 - 10/2007
5	Galectins (Galectin)IBA 04/2016 - 04/2005
5	narciclasineIBA 03/2013 - 09/2007
4	DNA (Deoxyribonucleic Acid)IBA 11/2021 - 04/2005
4	IntegrinsIBA 04/2011 - 04/2005
4	GastrinsIBA 12/2004 - 09/2002
3	AlkaloidsIBA 02/2018 - 05/2012
3	1-nitrohydroxyphenyl-N-benzoylalanine (GAL 1)IBA 04/2016 - 11/2006
3	Biomarkers (Surrogate Marker)IBA 06/2011 - 01/2003
3	UNBS 1450IBA 09/2009 - 01/2008
3	Adenosine Triphosphate (ATP)IBA 03/2008 - 01/2008
2	Ion Channels (Ion Channel)IBA 01/2021 - 07/2018
2	Bevacizumab (Avastin)FDA Link 11/2020 - 12/2008
2	Glutamic Acid (Glutamate)FDA Link 07/2018 - 09/2013
2	MicroRNAs (MicroRNA)IBA 07/2018 - 02/2014
2	Histones (Histone)IBA 02/2018 - 01/2017
2	Sirtuin 1IBA 02/2018 - 01/2017
2	Amaryllidaceae AlkaloidsIBA 09/2016 - 07/2010
2	crinineIBA 09/2016 - 05/2012
2	GadoliniumIBA 01/2016 - 06/2004
2	Polysaccharides (Glycans)IBA 02/2014 - 04/2011
2	Carrier Proteins (Binding Protein)IBA 02/2014 - 04/2011
2	CXC ChemokinesIBA 12/2013 - 05/2011
2	Cytotoxins (Cytolysins)IBA 06/2013 - 05/2007
2	Phosphotransferases (Kinase)IBA 07/2012 - 06/2010
2	Messenger RNA (mRNA)IBA 05/2012 - 09/2005
2	S100 Proteins (S 100 Protein)IBA 06/2011 - 08/2002
2	Caveolin 1IBA 04/2011 - 04/2009
2	Galectin 3 (LGALS3)IBA 01/2010 - 01/2003
2	CardenolidesIBA 09/2009 - 03/2008
2	Complement System Proteins (Complement)IBA 02/2009 - 04/2005
2	NaphthalimidesIBA 01/2009 - 08/2007
2	Cisplatin (Platino)FDA LinkGeneric 10/2007 - 03/2006
2	Cimetidine (Biomet)FDA LinkGeneric 05/2006 - 04/2005
2	RNA (Ribonucleic Acid)IBA 04/2005 - 01/2003
2	CollagenIBA 04/2005 - 09/2002
2	Cholecystokinin (Pancreozymin)IBA 12/2004 - 01/2003
2	Cholecystokinin B ReceptorIBA 04/2003 - 01/2003
1	TrabectedinIBA 01/2022
1	dabrafenibIBA 01/2022
1	olaparibIBA 11/2021
1	O-(6)-methylguanineIBA 11/2021
1	MethyltransferasesIBA 11/2021
1	ProdrugsIBA 11/2021
1	TubulinIBA 02/2018
1	BenzopyransIBA 01/2017
1	Urea (Carbamide)FDA LinkGeneric 01/2017
1	Histone Deacetylases (Histone Deacetylase)IBA 01/2017
1	compound 18IBA 01/2017
1	SirtuinsIBA 01/2017
1	5,10b-ethanophenanthridineIBA 09/2016
1	ChitosanIBA 04/2016
1	SuspensionsIBA 04/2016
1	DNA Transposable Elements (Element, IS)IBA 01/2016
1	Contrast MediaIBA 01/2016

Therapy/Procedure

21	Drug Therapy (Chemotherapy) 01/2021 - 08/2002
17	Therapeutics 01/2022 - 08/2002
11	Radiotherapy 11/2021 - 04/2006
6	Immunotherapy 01/2021 - 10/2007
3	Catheters 09/2008 - 06/2004
2	Chemoradiotherapy 08/2013 - 04/2012
1	Surgical Decompression 11/2020
1	Chemoprevention 10/2017
1	Intranasal Administration 04/2016
1	Intravenous Injections 01/2016